Neuroepigenetic Mechanisms of Action of Ultrashort Peptides in Alzheimer’s Disease
Author list available on linked original paper · 2022 · International Journal of Molecular Sciences 23(8):4259
What does this source report?
Develops hypotheses connecting short peptides with gene regulation and neurodegenerative processes. Hypotheses are retained as mechanistic proposals, not clinical conclusions.
- Population and setting
- Review of earlier research
- Evidence type
- Review
- Preparation
- See the original report; formulation details require verification.
- Source language
- English
- Title provenance
- Title as recorded in the linked source or index. A separate original-language title has not been transcribed unless shown above.
What are the limitations?
- Source-linked does not mean a completed risk-of-bias review.
- A review is not an independent clinical replication; proposed mechanisms do not establish efficacy or safety.
Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.
Source access and review scope
Source scope and bibliographic record checked; underlying experiments require individual appraisal.
Recorded source-check date: 2026-09-27. This date does not imply a completed systematic review.
Open original source or index record ↗
DOI: 10.3390/ijms23084259
Cite and trace this record
Original source: Author list available on linked original paper. Neuroepigenetic Mechanisms of Action of Ultrashort Peptides in Alzheimer’s Disease International Journal of Molecular Sciences 23(8):4259 2022.
Molekul research summary: https://molekul.io/research/neuroepigenetics-2022. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entryRelated compound profiles
Pinealon
A peptide research entry in the Khavinson evidence map. Direct studies, related extract findings, institute reports and unresolved claims are distinguished below.
KED
A tripeptide research entry connected to experimental neurodegeneration work. No human benefit is inferred from mouse-model findings.
Epitalon
AEDG was detected in pineal complex, but the long-term Epithalamin patient studies concern the extract. Synthetic-peptide effects require their own evidence.